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Parameter estimates for associated genetic variants, report ed in
the initial discovery samples, are often grossly inflated compared to
the values observed in the follow-up replication samples. This type of
bias is a consequence of the sequential procedure in which the esti-
mated effect of an associated genetic marker must first pass a strin-
gent significance threshold. We propose a hierarchical Bayes method
in which a spike-and-slab prior is used to account for the possibility
that the significant test result may be due to chance. We examine
the robustness of the method using different priors corresponding to
different degrees of confidence in the testing results and propose a
Bayesian model averaging procedure to combine estimates produced
by different models. The Bayesian estimators yield smaller variance
compared to the conditional likelihood estimator and outperform the
latter in studies with low power. We investigate the performance of
the method with simulations and applications to four real data ex-
amples.
1. Introduction. Parameter estimates such as odds ratios (OR) for an
associated genetic variant (e.g., SNP, Single-Nucleotide Polymorphism), re-
ported from the same discovery samples that were initially used to declare
statistical significance, are often grossly inflated compared to the values ob-
served in the follow-up replication samples [e.g., Nair, Duffin and Helms
(2009)]. This type of bias is a consequence of using the same data for both
model selection and parameter estimation, because a declared associated
variant must pass a stringent significance threshold. This phenomenon is
also known as the Beavis effect [Xu (2003)] or the winner’s curse [Zo¨llner
and Pritchard (2007)] in the biostatistics literature.
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The winner’s curse has recently gained much attention in genetic studies,
because it has been recognized as one of the major contributing factors to
the failures of many attempted replication studies [e.g., Ioannidis, Thomas
and Daly (2009)]. For example, five Nature Genetic publications in the first
three months of 2009 acknowledged the effect of the winner’s curse [e.g.,
Nair, Duffin and Helms (2009)]. In their recent Nature Review paper, Ioan-
nidis, Thomas and Daly (2009) dedicated a section to the winner’s curse and
emphasized that “the magnitude of the winner’s curse is inversely related to
the power of the study. In typical circumstances, for 10% power, the infla-
tion of an additive effect could be approximately 60%. . . . For small effects
[anticipated for susceptibility loci associated with complex diseases/traits],
even large meta-analyses could be grossly under-powered and emerging as-
sociations could be considerably inflated. For rare variants, the power can
be <1%.”
Some authors [e.g., Go¨ring, Terwilliger and Blangero (2001)] have argued
that reliable parameter estimates can be obtained only from an indepen-
dent sample. However, collecting additional samples could be undesirable
due to, for example, time and budget constraints as well as concerns over
population heterogeneity and sampling differences. Two categories of meth-
ods were subsequently proposed to correct for the selection bias using the
original samples only: the model-free resampling based methods [Sun and
Bull (2005); Wu, Sun and Bull (2006); Yu et al. (2007); Jefferies (2007)] and
the likelihood based methods [Zo¨llner and Pritchard (2007); Ghosh, Zou and
Wright (2008); Zhong and Prentice (2008); Xiao and Boehnke (2009)]. Both
types of approaches were shown to substantially reduce the estimation bias
in relatively small samples, and comparable performances were observed by
Faye et al. (2009). However, one caveat is that the variances of the proposed
estimators in both categories are considerably higher than the original na¨ıve
estimator and lead to highly variable estimates of the sample size needed for
replication studies. Although the increased variability is expected, due to the
bias-variance trade-off, it may be too high to provide practical design rec-
ommendations. For example, Figure 4 of Zo¨llner and Pritchard (2007) shows
that the bias-adjusted sample size estimates range from ∼500 to ∼100,000
compared to the actual required sample size of 1,261 for a successful repli-
cation study (α= 10−6, power = 80%).
Motivated by the above observations and the fact that some form of prior
information is often available in genetic studies, we propose here a Bayesian
framework to further reduce the bias and decrease the variability in the
estimates. In particular, we focus on the OR estimates from genome-wide
association studies (GWAS) via logistic regression analyses of case-control
disease status, because most of the current genetic mapping studies adopt
the case-control GWAS design. We first describe the statistical model in
Section 2. We prove in Section 3 that, conditional on statistical significance,
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there are no unbiased estimators for the log OR. We present the Bayesian
methodology in Section 4 with detailed discussions on the prior specifica-
tions and the advantages of model averaging. We assess the performance of
the proposed methods in Section 5 via extensive simulation studies under
a general normal model and specific genetic models. We demonstrate the
utility of our methods in Section 6 with applications to four different asso-
ciation studies, including a candidate gene study and three GWAS of either
binary case-control or quantitative outcomes. Our concluding remarks are
in Section 7.
2. The statistical model. Let β refer to the true log Odds Ratio (OR),
the parameter of interest, for the risk allele of an associated SNP, and Z the
statistic of the corresponding association test. Following Ghosh, Zou and
Wright (2008), we assume that Z is asymptotically normally distributed
and has the form
Z =
β̂
ŜE(β̂)
∼N
(
β
SE(βˆ)
,1
)
,
where β̂ is the estimate for β from the logistic regression, logit(E[Y ]) =
α+βX , in which the response variable Y is the affection status of a sample
(0 = unaffected and 1 = affected by the disease of interest) and the predictor
X ∈ {0,1,2} is the SNP genotype coded additively (X represents the number
of copies of the risk allele). Other covariates may be also included in the
model. Without loss of generality, we assume that the minor allele is the
risk allele and the alternative of interest is one-sided, that is, H0 :β = 0 vs.
H1 :β > 0. The association test in this case is based on the Wald test, and
if the null hypothesis is rejected, the standard practice is to directly use the
β̂ from the logistic regression as the estimate for β.
The above estimation procedure is essentially the same as the familiar
practice of population mean estimation in the following more general sta-
tistical setup. Assuming that n i.i.d. samples, {X1, . . . ,Xn}, were collected
from a normal population with mean µ and variance σ2, a significance test is
first conducted for H0 :µ= 0 vs. H1 :µ > 0 based on the statistic, Tn =
X
S/
√
n
,
which follows N( µ
σ/
√
n
,1), where X and S are the sample mean and standard
deviation. The sample mean X , calculated from the same sample, is subse-
quently used as an estimate for µ, without adjusting for the fact that the
null hypothesis was rejected (i.e., Tn > c, where c is the critical value corre-
sponding to type I error rate α) and that estimation is performed for sam-
ples with positive findings only. Note that, in our simplified model, although
E[X ] = µ, the conditional mean E[X |X > (cS/√n)] is strictly greater than
µ, unless the power of the test is 100%. Thus, this na¨ıve estimate, X , is
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upward biased. The amount of bias is inversely proportional to the power
as was first demonstrated by Go¨ring, Terwilliger and Blangero (2001) in
genome-wide linkage analyses and later by Garner (2007) for genome-wide
association studies. The likelihood based methods proposed by Ghosh, Zou
and Wright (2008) and others propose to correct for this selection bias by
calculating the maximum likelihood estimate (MLE) of µ from the correct
conditional likelihood. In this setting,
P (X|µ,σ2, Tn > c) =
n∏
i=1
(1/
√
2πσ2) exp[−(Xi − µ)2/2σ2]
1−Φ(c− µ/(σ/√n)) ,(2.1)
where Φ is the cumulative distribution function (c.d.f.) of the standard nor-
mal distribution.
Although the above normal model is a conceptual one, it connects directly
with the logistic model used for case-control association studies. Specifically,
β (the true log OR) corresponds to µ (the normal population mean), β̂ (the
na¨ıve estimate) corresponds to the statistic X , and ŜE (β̂) corresponds to
S/
√
n. In the following development of the bias correction Bayesian meth-
ods, we choose to focus on the normal model for a number of reasons. The
key factor that influences the selection bias is the power of the association
test, which depends on the noncentrality parameter, β/SE (βˆ). In practice,
β is the true log OR, but SE(βˆ) is a complex function of multiple compo-
nents including the prevalence of the disease in the population, the disease
model (e.g., additive, dominant or others), the minor allele frequency of
the SNP, the sample size and the significance threshold used [Slager and
Schaid (2001)]. The normal model allows us to concisely control the main
factor of interest, the power of the association test, in the simulation studies,
by fixing the normal population mean (µ↔ β, the log OR) and consider-
ing practically meaningful ranges of significance threshold value, power and
sample size (n), which in turn determine the normal population variance [σ,
and σ/
√
n↔ SE (βˆ)]. Moreover, this conceptual normal model also covers
association analyses of quantitative outcome, Y, for which a linear regres-
sion model is typically used, for example, E[Y ] = α+ βX . In that case, the
population mean µ in the conceptual normal model represents the regres-
sion coefficient β. In Section 6 we show how our Bayesian methods built
upon this conceptual normal model can be applied to published association
studies for which only the OR (or the regression coefficient), the association
p-value, the sample size and the significance threshold were available.
In the following, we first show that there are no unbiased estimators for
the population mean conditionally on the significance of the corresponding
hypothesis test. We then proceed with the development of a catalogue of
Bayesian estimators and the evaluation of their performance via simulation
and application studies.
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3. Lack of unbiased estimators for µ. Ghosh, Zou and Wright (2008) and
other authors have demonstrated that the MLE from the correct conditional
likelihood could substantially reduce the bias. However, they also observed
via simulation studies that the conditional MLE tends to over-correct for
large µ and under-correct for small µ. Stallard, Todd and Whitehead (2008)
showed that there is no conditional unbiased estimators for the effect of
treatment A from a sample that was first used to select treatment A over
B, that is, conditioning on the fact that the sample effect of treatment
A was larger than that of treatment B. Although previous authors [Zhong
and Prentice (2008); Bowden and Dudbridge (2009)] discussed that a similar
argument can be used in the case considered here, below we provide a formal
proof to show that there are no unbiased conditional estimators for the
population mean µ even when the population variance σ2 is known.
Because Tn is a sufficient statistic for µ when σ is known, the completeness
of the normal family of distributions implies that we can restrict the search
for unbiased estimators of µ
σ/
√
n
to functions of Tn. Now suppose that some
function h(Tn) is an unbiased estimator of
µ
σ/
√
n
conditional on the statistical
significance, that is, Tn > c. Let g(Tn) = {Tn − h(Tn)}, then
E[g(Tn)|Tn > c] = E[Tn|Tn > c]−E[h(Tn)|Tn > c]
=
∫ ∞
c
Tn
φ(Tn − µ/(σ/
√
n))
1−Φ(c− µ/(σ/√n)) d(Tn)−
µ
σ/
√
n
=
1
B
∫ ∞
c−µ/(σ/√n)
(
z +
µ
σ/
√
n
)
φ(z)dz − µ
σ/
√
n
=
1
B
[∫ ∞
c−µ/(σ/√n)
z · e−z2/2 dz +B · µ
σ/
√
n
]
− µ
σ/
√
n
=
1
B
[
φ
(
c− µ
σ/
√
n
)
+B · µ
σ/
√
n
]
− µ
σ/
√
n
=
φ(c− µ/(σ/√n))
1−Φ(c− µ/(σ/√n)) ,
where B = 1−Φ(c− µ
σ/
√
n
).
Thus, we have∫ ∞
c
g(Tn)
φ(Tn − µ/(σ/
√
n))
1−Φ(c− µ/(σ/√n)) dTn =
φ(c− µ/(σ/√n))
1−Φ(c− µ/(σ/√n)) ,(3.1)
which implies∫ ∞
c
g(Tn)φ
(
Tn − µ
σ/
√
n
)
dTn = φ
(
c− µ
σ/
√
n
)
.(3.2)
6 L. XU, R. V. CRAIU AND L. SUN
Now, let δc(y) be the Dirac delta function defined for y ≥ c such that it is
equal to 0 for all y greater than c and
∫ ǫ
c δc(y)dy = 1 for all ǫ > 0. It is easy to
see that a solution to equation (3.2) is g(Tn) = δc(Tn). By the completeness
of the normal distribution, the solution g(Tn) · 1{Tn>c} is unique almost
everywhere. Thus, h(Tn) · 1{Tn>c} = Tn · 1{Tn>c} holds almost everywhere.
Hence, Tn is also an unbiased estimator for
µ
σ/
√
n
. However, Tn ·1{Tn>c} has
an upward bias equal to φ(c−µ/(σ/
√
n))
1−Φ(c−µ/(σ/√n)) . Therefore, we conclude that there
are no unbiased estimators of µ
σ/
√
n
and hence no unbiased estimators of µ.
4. Bayesian bias correction.
4.1. Prior specification. The possible available prior information for genome-
wide association studies (GWAS) is diverse due to, for example, results from
previous genome-wide linkage analyses or candidate studies, or biological ev-
idence on the SNPs. One common theme, however, is the anticipated low
power of the GWAS and the well-acknowledged fact that an apparent signifi-
cantly associated SNP could be a false positive [Ioannidis, Thomas and Daly
(2009)]. Thus, the performance of the proposed Bayesian methods is assessed
in this context, although the practical implementation of the methods could
be study specific depending on the type of the available prior.
The Bayesian paradigm allows us to incorporate in our model the prior
belief that the significance of the effect observedmay be due to chance. Math-
ematically, this belief can be modeled using a spike-and-slab prior which is
essentially a mixture between a discrete probability with mass at zero and
a continuous density f with support on the positive real line
p(µ|ξ) = ξδ{0}(µ) + (1− ξ)f(µ),
where ξ is either constant or a hyperparameter in the model.
The spike-and-slab priors have a long history in the Bayesian literature
on variable selection and shrinkage estimation, for example, Box and Meyer
(1986), Mitchell and Beauchamp (1988), George and McCulloch (1993),
Chipman (1996), Clyde, DeSimone and Parmigiani (1996), Geweke (1996),
and Kuo and Mallick (1998). A recent theoretical study by Ishwaran and
Rao (2005) discusses the similarities between Bayesian procedures using the
spike-and-slab priors and frequentist procedures.
We treat ξ as a hyperparameter with a Beta distribution, ξ ∼ Beta(a, b).
The parameters a, b reflect our degree of prior belief in µ= 0 (false positive)
versus µ > 0 (true positive). If we set a = b = 1, then p(ξ|a = 1, b = 1) is
the Uniform(0,1) density, which implies that we do not favor, a priori, any
region of (0,1). This could be considered the “noninformative” prior for ξ.
The choice a = 2/3 and b = 2/3 corresponds to our belief in two extreme
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Fig. 1. Density of the prior Beta(a, b) for ξ with different choices of a and b.
outcomes: ξ is either close to 0 (believing in true positive, µ > 0) or close to
1 (believing in false positive, µ= 0). Smaller values for a and larger values
for b, say, a= 0.5 and b= 8, lead to a higher prior confidence that the signal
is real. Similarly, larger values for a and smaller values for b, say, a= 8 and
b = 0.5, correspond to prior skepticism regarding the observed association
between the significant SNP and the trait of interest. Figure 1 shows the
Beta distribution of ξ for different values of a and b.
Although we focus on Beta(0.5, 8), and Beta(8, 0.5) in evaluating the
performance of the proposed Bayesian methods, we conducted additional
simulations to study the model’s robustness to the choice of priors. Sim-
ulation results included in the supplementary material indicate that other
values for a and b [e.g., Beta(0.5, 16) or Beta(4, 0.5)] that preserve the L-
shaped or the “inverse” L-shaped density, as seen in Figure 1, produce very
similar inferences.
In the existing likelihood approaches the sample variance, S2, is typically
used to estimate σ2 [Ghosh, Zou and Wright (2008)]. Although the variance
estimator has relatively high precision in large samples, it could be subject
to the selection bias in small samples [Faye et al. (2009)]. Therefore, we
adopt an empirical Bayes prior for σ2 in which the hyperparameters of the
inverse gamma distribution, α1 and α2, are chosen so that the a priori mean
of σ2 is equal to S2, the sample variance, but the prior variance of σ2 is equal
to 200. We note that additional simulations with more certainty about σ2
(prior variance of σ2 as small as 10) or less certainty (as large as 1000)
produce very similar results.
We use Uniform(0,A) to specify f(µ), the density function for the con-
tinuous component of the prior for µ, the log OR, where A represents the
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upper bound of log OR. However, in this parametrization the estimator is
very sensitive to the choice of A. To show this, let Z be the latent mixture
indicator so that Z = 0 if the significant SNP is a false positive (µ= 0) and
Z = 1 for a true positive (µ > 0). It is not difficult to see that
Z| ~X, ξ,µ,σ2 =


0, with probability
p0
p0 + p1
,
1, with probability
p1
p0 + p1
,
where ~X = {X1, . . . ,Xn} and
p0 =
ξ
1−Φ(c) ,
p1 =
1
A
× (1− ξ) exp{−(1/(2σ
2))(nµ2 − 2µ∑ni=1Xi)}
1−Φ(c− µ/(σ/√n)) .
Thus, depending on the value of A, p1 can be made arbitrarily small regard-
less of the data available. This can influence dramatically (even for A= 2)
the performance of the computational algorithm used to obtain the poste-
rior distribution of interest (described in Section 4.3). One simple method
to circumvent this problem is to use the reparametrization θ = µ/A which
dissolves the influence of A on p1. Therefore, the proposed Bayesian method
has the following hierarchical prior structure:
p(θ|ξ) = ξg0(θ) + (1− ξ)g1(θ),(4.1)
ξ ∼ Beta(a, b),
σ2 ∼ Inv-Gamma(α1, α2),
where α1 = S
4/200 + 2, and α2 = S
6/200 + S2, S is the sample standard
deviation, g0(θ) = δ{0}(θ) and g1(θ) is the density of Uniform(0, 1).
In the actual implementation, we use A= 2 to reflect the known maximum
log OR of SNPs identified for complex diseases and traits. For example, the
truly associated SNP in the well-known major histocompatibility complex
(MHC) region has perhaps the highest genetic effect observed to date, with a
log OR of log(5.49) = 1.7 [WTCCC (2007)]. We note that additional simula-
tions showed that, as long as the reparametrization θ = µ/A is used, results
remain largely the same for higher upper bounds (e.g., A= 6 corresponding
to a maximum OR≈ 400). Applications in Section 6 also demonstrate the
robustness of the model when it was applied not only to case-control data
but also to an association study of a quantitative outcome.
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4.2. Posterior distribution. The joint prior distribution for (θ, ξ) is
p(θ, ξ) = p(θ|ξ)p(ξ)
(4.2)
= ξg0(θ)ξ
a−1(1− ξ)b−1 + (1− ξ)g1(θ)ξa−1(1− ξ)b−1.
Conditional on Z, the sampling distribution is
P ( ~X |θ,σ2,Z,Tn > c)
∝ (1/σ)n
(
exp{−∑ni=1X2i /(2σ2)}
1−Φ(c)
)1−Z
×
(
exp{−∑ni=1 (Xi − 2θ)2/(2σ2)}
1−Φ(c− 2θ/(σ/√n))
)Z
.
If Z were observed, the posterior distribution for the vector (θ, ξ, σ2) would
be
p(θ, ξ, σ2| ~X,Z,Tn > c)
∝ p( ~X,Z|θ,σ2, Tn > c)p(θ|ξ)p(ξ)p(σ2)
∝ (1/σ)n
(
exp{−∑ni=1X2i /(2σ2)}ξ
1−Φ(c)
)1−Z
(4.3)
×
(
exp{−∑ni=1 (Xi − 2θ)2/(2σ2)}(1− ξ)
1−Φ(c− 2θ/(σ/√n))
)Z
× ξa−1(1− ξ)b−1
(
1
σ2
)α1+1
exp{−α2/σ2}
for θ, ξ ∈ [0,1], σ > 0 (detailed derivation provided in the Supplementary
material). We note that the posterior distribution specified in equation
(4.3) depends on the data only through the sufficient statistics for (µ,σ2),
Dn = (
∑
Xi,
∑
X2i ). This is particularly useful in practice when the origi-
nal sample-specific data ~X are not available, but the sufficient statistics are
provided or could be inferred from typically reported quantities such as the
sample size, the observed OR and association p-value, and the significance
threshold used.
4.3. Sampling from the posterior distribution. The latent variable Z is
unobservable in practice, so equation (4.3) cannot be used directly to study
the characteristics of the posterior distribution, π(θ, ξ, σ2) = p(θ, ξ, σ2|Dn,
Tn > c). The traditional approach in this type of situation is to use Markov
chain Monte Carlo (MCMC) techniques to sample from π. The posterior
distribution has a mixture form for which the Data Augmentation algorithm
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of Tanner and Wong (1987) has been proven extremely efficient [see also
van Dyk and Meng (2001)]. The algorithm relies on sampling alternatively
from the distribution of Z|Dn, θ, ξ, σ2 and θ, ξ, σ2|Z,Dn. More precisely, at
iteration t we carry out the following steps:
Step 1. Sample Zt ∈ {0,1} given ξt−1, θt−1 and σ2t−1 from the conditional
distribution
Zt|ξt−1, θt−1, σ2t−1 =


0, with probability
p0
p0 + p1
,
1, with probability
p1
p0 + p1
,
where
p0 =
ξt−1
1−Φ(c) ,
p1 =
(1− ξt−1) exp{−(1/(2σ2t−1))(4nθ2t−1 − 4θt−1
∑n
i=1Xi)}
1−Φ(c− 2θt−1/(σt−1/
√
n))
.
Step 2. (i) If Zt = 0, sample
ξt ∼ Beta(a+1, b),
σ2t ∼ p(σ2|Dn)∝
(
1
σ2
)n/2+α1+1
exp
{
− 1
σ2
(
α2 +
∑n
i=1X
2
i
2
)}
,
which is the inverse gamma distribution with shape parameter equal to
n
2 +α1, and scale parameter equal to α2 +
∑n
i=1X
2
i
2 . We also set µt = θt = 0.
(ii) If Zt = 1, sample
ξt ∼ Beta(a, b+ 1),
θt ∼ p(θ|Dn, σt−1)∝
exp{−2nθ2/σ2t−1 − 2θ
∑n
i=1Xi/σ
2
t−1}
1−Φ(c− 2θ/(σt−1/
√
n))
1(0,1)(θ),
σ2t ∼ p(σ2|(Dn, ξt, θt)∝
exp{−1/(2σ2)(∑ni=1X2i + 4nθ2t − 4θt∑ni=1Xi)}
(1−Φ(c− 2θt/
√
σ2/n))
× (σ2)n/2+α1+1 exp{−α2/σ2}.
The sampling of θt and σ
2
t at step 2(ii) cannot be carried out directly, so
we apply a Metropolis–Hasting algorithm [Metropolis et al. (1953)]. We use
20,000 iterations to obtain 15,000 posterior samples, discarding the first
5000 “burn-in” samples. The sample mean of the above 15,000 posterior
samples, θ, is used to estimate the posterior mean E[µ|Dn, Tn > c]. That is,
µ̂B = 2θ, where the factor 2 is due to the initial reparametrization θ = µ/A
and A= 2. (Additional simulations presented in the Supplementary material
show that running the chain longer or discarding more “burn-in” samples
provide similar results.)
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4.4. Bayesian Model Averaging (BMA). The Bayesian model averaging
(BMA) is a coherent and conceptually simple method devised to take into
account the model uncertainty [see Hoeting et al. (1999) and references
therein]. For the problem discussed here, the uncertainty is related to our
lack of information regarding the power of the test performed in the first
stage. If we knew, say, that the power of the test is high, then we would
be more confident that the signal detected is a true signal and this would
be reflected in our choice of the prior. In the absence of such information,
one could adopt the BMA methodology to increase the robustness of the
Bayesian estimator.
In the BMA paradigm, assume that ∆ is the quantity of inferential interest
for which a number of candidate models, say, M1, . . . ,MK , are available.
Given the prior probability for each candidate model, p(Mi),1≤ i≤K, the
traditional BMA method assigns the posterior distribution given data D
for ∆
p(∆|D) =
K∑
k=1
p(∆|Mk,D)p(Mk|D),(4.4)
where
p(Mk|D) = p(D|Mk)p(Mk)∑K
l=1 p(D|Ml)p(Ml)
and
p(D|Mk) =
∫
p(D|θk,Mk)p(θk|Mk)dθk.
In our setting, K = 2 because only two models are considered. Let M1 be
the model with prior p(ξ) = Beta(8,0.5) (a priori favors the belief that the
initial discovery is a false positive) and M2 for p(ξ) = Beta(0.5,8) (a priori
favors the belief that the initial discovery is a true positive). To specify the
values for p(M1) and p(M2), we utilize the threshold value c in the following
fashion, p(M1) = e
(−c/2) and p(M2) = 1− e(−c/2). Thus, our prior belief in
model M1 (with higher density for false positive) decreases as the testing
threshold value increases at an exponential rate. The posterior probabilities
for the two models can be derived as
p(Mi|Dn) = p(Dn|Mi)p(Mi)
p(Dn|M1)p(M1) + p(Dn|M2)p(M2) , i= 1,2.
Thus,
p(M1|Dn)
p(M2|Dn) =
p(Dn|M1)
p(Dn|M2) ·
e(−c/2)
(1− e(−c/2)) .(4.5)
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The direct computation, however, is difficult because the integral
p(Dn|M) =
∫ ∫
(µ,ξ,σ2)
p(Dn|µ, ξ, σ2,M)p(µ|ξ,M)p(ξ|M)p(σ2|M)dµdξ
cannot be calculated in a closed form. Note that
p(µ, ξ, σ2|Dn,M) = p(Dn|M,µ, ξ, σ
2)p(µ|ξ,M)p(ξ|M)p(σ2|M)
p(Dn|M) ,(4.6)
thus p(Dn|M) can be viewed as the normalizing constant of the posterior
distribution p(µ, ξ, σ2|Dn,M). Therefore, the first ratio in (4.5) is a ratio of
two normalizing constants for two densities from which we can sample. The
problem of estimating ratios of two normalizing constants has been discussed
by, among others, Meng and Wong (1996) and Gelman and Meng (1998).
We use the bridge sampling method proposed by Meng and Wong (1996) to
compute the ratio in (4.5).
To compute (4.5), let r= p(Dn|M1)/p(Dn|M2), ω = (µ, ξ, σ2), πi = p(µ, ξ,
σ2|Dn,Mi) and qi(µ, ξ, σ2) = p(Dn|Mi, µ, ξ, σ2)p(µ|ξ,Mi)p(ξ|Mi)p(σ2|Mi), for
1≤ i≤ 2. Given m= 10,000 samples {(µi1, ξi1, σ2i1), . . . , (µini , ξini , σ2i1)} from
each density πi, we can approximate r using the iterative procedure of Meng
and Wong (1996). Specifically, after starting with an initial estimate rˆ(0), at
the (t+1)st iteration, we compute
rˆ(t+1) =
(1/m)
∑m
j=1[q1(ω2j)/(s1q1(ω2j) + s2rˆ
(t)q2(ω2j))]
(1/m)
∑m
j=1[q2(ω1j)/(s1q1(ω1j) + s2rˆ
(t)q2(ω1j))]
(4.7)
≡ (1/m)
∑n2
j=1[l2j/(s1l2j + s2rˆ
(t))]
(1/m)
∑m
j=1[1/(s1l1j + s2rˆ
(t))]
,
where si = 0.5, and lij =
q1(ωij)
q2(ωij)
, for 1≤ j ≤m, 1≤ i≤ 2. Note that lij needs
to be computed only once at the beginning of the algorithm. The convergent
value of rˆ(t) is the one we choose to estimate r.
In the current setting lij is easy to compute since
lij =
p(Dn|M1, µij, ξij , σ2ij)p(µij |ξij,M1)p(ξij |M1)p(σ2ij |M1)
p(Dn|M2, µij, ξij , σ2ij)p(µij |ξij,M2)p(ξij |M2)p(σ2ij |M2)
=
p(ξij|M1)
p(ξij|M2) = ξ
7.5
ij (1− ξij)−7.5.
From equations (4.4) and (4.5), we obtain the BMA estimator of µ,
µˆBMA =
rˆe(−c/2)
rˆe(−c/2) + 1− e(−c/2) µˆ1 +
1− e(−c/2)
rˆe(−c/2) +1− e(−c/2) µˆ2,(4.8)
where µˆ1 and µˆ2 are the posterior means of µ obtained under models M1
and M2, respectively.
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5. Simulation study. We carried out two sets of simulations to examine
the performances of the Bayesian methods and compared the results with
those from the likelihood-based estimators of Ghosh, Zou and Wright (2008).
The first set of simulations used data generated from the normal model that
was used to outline and develop the Bayesian methods, and the second set
used data simulated from a case-control genetic model. The nine estimators
examined are as follows:
N: The na¨ıve estimator (X , the unconditional MLE).
MLE: The conditional MLE estimator based on equation (2.1), that is the
β1 estimator in Ghosh, Zou and Wright (2008).
NMLE: The mean of the Normalized Conditional Likelihood estimator, that
is, the β2 estimator of Ghosh, Zou and Wright (2008).
Ghosh: The average estimator of MLE and NMLE, that is, the β3 estimator
recommended by Ghosh, Zou and Wright (2008).
B.L: The Bayesian estimator based on equation (4.3) when the prior for ξ is
Beta(8,0.5) (the prior belief is low power of the initial discovery study).
B.H: The Bayesian estimator based on equation (4.3) when the prior for ξ is
Beta(0.5,8) (the prior belief is high power of the initial discovery study).
B.BMA: The BMA estimator obtained by averaging the B.L and B.H mod-
els, based on equation (4.8).
B.M: The Bayesian estimator based on equation (4.3) when the prior for ξ
is Beta(2/3,2/3) (the prior belief is either low or high power).
B.Unif: The Bayesian estimator based on equation (4.3) when the prior for
ξ is Uniform(0,1) (the “noninformative” prior).
Whenever an obtained estimate was negative, it was truncated to be zero
following the standard practice of interpreting the “flip–flop” phenomenon
occurring at the same SNP in the same population [Lin et al. (2007)]. That
is, a SNP is found to be associated with the disease of interest in two inde-
pendent studies, but the risk allele is reversed (i.e., the allele that increases
the risk in one study is the protective allele that decreases the risk in another
study).
5.1. Simulation set 1—normal model. We considered a factorial design
in which the factors are the power of the association test, the type 1 error
rate and the sample size. The power levels are {5%,10%,20%, 50%,99%}, of
which 99% allows us to investigate the asymptotic behavior of the methods
while 20% or lower reflect the low power anticipated for genome-wide asso-
ciation studies (GWAS). The type 1 error rates, α, are {0.05,10−4,10−6},
of which 0.05 is the typical choice for a single SNP study, while the other
two are suitable for high-throughput GWAS depending on the density of
the SNPs being genotyped. The corresponding threshold values for the test
statistics, c, are {1.645,3.719,4.753}. The true population mean is fixed
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Fig. 2. Performance of the nine estimators under the normal model with a type 1 error
rate of 0.05. The population mean µ = log(1.1) = 0.0953 and power ranging from 10%,
20%, 50% to 99%. Details of the simulating parameters are given in row 1 of Table 1. Each
circle represents an estimate, the horizontal is the averaged estimate over 200 simulated
data sets, and the long horizontal line represents the true value of µ. The Bias, sample
Standard Deviation (SD) and Root Mean Squared Error (RMSE) are also provided for
each estimator.
at µ = 0.095 = log(1.1), and the sample size ranges from n = 100 to over
10,000 depending on the combination of α and power. The values of the
these parameters then uniquely determine the corresponding population
variance, σ2. The details of each simulation scenario are shown in Table 1.
Under each simulation scenario, we began by generating 200 significant
data sets, that is, Xi ∼ N(µ,σ2), i = 1, . . . , n, such that the value of the
test statistic, Tn =
X
S/
√
n
, is greater than c. We then computed the nine
estimates, N, MLE, NMLE, Ghosh, B.L, B.H, B.BMA, B.M and B.Unif, for
each significant data set.
Figure 2 provides detailed results when the type 1 error rate is 0.05 and
the simulating parameter values are those in row 1 of Table 1. These plots
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Table 1
Simulation scenarios for the normal model
5% 10% 20% 50% 99%
α\power n σ σ/√n n σ σ/√n n σ σ/√n n σ σ/√n n σ σ/√n
0.05 – – – 100 2.623 0.262 200 1.678 0.119 1000 1.832 0.058 5000 1.697 0.024
10−4 1000 1.453 0.046 2000 1.749 0.039 3000 1.814 0.033 5000 1.812 0.026 10,000 1.577 0.016
10−6 2000 1.371 0.031 4000 1.736 0.027 5000 1.723 0.024 8000 1.793 0.020 16,000 1.702 0.013
Notes: Sample size (n) and population standard error (σ) needed to obtain the desired power at the prespecified type 1 error rate (α)
when population mean µ= 0.0953 = log(1.1).
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confirm that, in the case of low power of the initial association study (e.g.,
10%), the na¨ıve estimator has a large upward bias. Even in the moderately
powered studies (e.g., 20%), the na¨ıve estimator could considerably overes-
timate the true effect size. Note that the two priors with opposite degrees of
belief in the significance of the effect, B.L and B.H, produce quite different
results. The B.L estimator conservatively shrinks the effect and, therefore, it
is more reliable in those cases when the effect is small or zero. (See additional
figures in Supplement for the case of no genetic effect, i.e., the apparent as-
sociation is a false positive.) When the power of the test is relatively high
(e.g., 50%), B.H outperforms the other estimators considered. While it is
clear that B.L and B.H are complementing each other, B.BMA, designed to
balance between B.L and B.H, performs well in a variety of settings. The
performances of the other two estimators, B.M and B.Unif, are similar to
one another but inferior to B.BMA. The natural implication is that putting
equal prior weight on (0,1) is equivalent to putting equal weight on ξ close
to zero or close to 1. As expected, when the power is very high (e.g., 99%)
there is little bias in the na¨ıve estimate; the other estimates also converge to
the true value with B.L lagging behind. This is due to the strong skepticism
embedded in the B.L model about the finding.
In most of the cases, the Bayesian estimators achieve the anticipated
reduction in bias as well as variance compared to the likelihood based es-
timators, MLE, NMLE and Ghosh. Of the three, we observed that Ghosh
(i.e., the average of MLE and NMLE) performs the best, confirming the
conclusion of Ghosh, Zou and Wright (2008). Therefore, in what follows we
focus on the comparison between B.BMA and Ghosh.
The advantage of B.BMA over Ghosh is especially obvious in the low
power studies. For example, when the power of the test is 10%, the bias
of Ghosh is 0.196, almost twice as big as 0.092 for B.BMA. The sample
standard deviation of the Ghosh estimate is 0.186 compared to 0.116 for the
B.BMA estimate. The Root Mean Squared Error (RMSE) for B.BMA is al-
most half that for Ghosh (0.148 vs. 0.273). To formally assess the significance
of the difference between Ghosh and B.BMA, we performed a matched-pair
t-test based on 50 simulation runs, and we obtained a t-statistic of −117.47
showing that the difference is significant. As expected, the advantage dissi-
pates and the two perform similarly when the power of the initial association
study increases.
As discussed by Ghosh, Zou and Wright (2008) and detailed in Section 2,
the main factor that influences the estimation bias is the power of the associ-
ation test which depends on the noncentrality parameter, µ/(σ/
√
n). Thus,
although µ has the interpretation of β = logOR and was fixed at log(1.1),
the results are qualitatively similar for larger OR with smaller sample size
or smaller OR with larger sample size, as long as the ratio, µ/(σ/
√
n), and
the significance threshold value, α, stay the same.
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Fig. 3. Performance of the nine estimators under the normal model with a type 1 error
rate of 10−6. The population mean µ = log(1.1) = 0.0953 and power ranging from 5%,
20%, 50% to 99%. Details of the simulating parameters are given in row 3 of Table 1.
Each circle represents an estimate, the horizontal bar is the averaged estimate over 200
simulated data sets, and the long horizontal line represents the true value of µ. The Bias,
sample Standard Deviation (SD) and Root Mean Squared Error (RMSE) are also provided
for each estimator.
Figure 3 shows the performance of the estimators when the type 1 error
rate is 10−6 and the parameter values are from row 3 of Table 1. We found
that all the bias correction estimators are showing a slight overcorrection.
(Note that the scale in the y-axis differs between Figures 2 and 3.) In this
setting, the results of B.BMA and Ghosh are very similar with B.BMA
having a smaller variance. The difference between Figures 2 and 3 is due to
the fact that the significance threshold used is drastically different, α= 0.05
for Figure 2 and α= 10−6 for Figure 3, while the power of the association
study of the same SNP is kept comparable by increasing the required sample
size, n. As a result, the noncentrality parameter values, µ/(σ/
√
n), are not
directly comparable between the two cases.
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5.2. Simulation set 2—genetic model. Following the setup of the sim-
ulations conducted by Ghosh, Zou and Wright (2008), we generated data
for 500 cases and 500 controls from an additive genetic model with disease
prevalence of 1%, minor allele frequency of 0.25, and the log OR, β, ranging
from log(1.1) to log(2). The threshold value is c= 5.0, leading to the signifi-
cance level α= 2.87× 10−7. For each log OR value, we began by generating
200 significant data sets such that the association test statistic, βˆ/ŜE (βˆ),
is greater than c, where βˆ is the log OR estimate obtained from the logistic
regression model, and ŜE (βˆ) is the estimate of the standard error of βˆ. Us-
ing the summary statistics, βˆ and ŜE(βˆ), the auxiliary information such as
the sample size (we used n= 1000) and the threshold value of the test, we
applied the Bayesian methods by letting µˆ= βˆ, and S = σˆ = ŜE (βˆ)×√n.
Figure 4 illustrates the results for log OR values equal to {log(1.2), log(1.3),
log(1.4), log(1.8)}, corresponding to the power of detecting the associated
SNP in the range {0.345%, 4.515%, 21.897%, 99.5%}. (Results for other log
OR values are qualitatively similar.) The results obtained from the simu-
lated genetic models confirm that the B.BMA has a smaller RMSE than
Ghosh when the power of the association test is low. Although the variance
reduction on the log OR scale is small, the implication on study design is
practically important. Figure 5 shows the sample size estimation for a repli-
cation study with 80% power at the 0.05 significance level using the na¨ıve
log OR estimate, the Ghosh estimate and the B.BMA estimate obtained
from the original discovery samples, as reported in Figure 4. Results show
that the standard error in sample size estimation based on Ghosh is almost
twice as big as that based on B.BMA when the power of the original as-
sociation study is low (e.g., 20% or lower). In the low power case, we also
note that the sample size predicted based on N, the na¨ıve estimate, is never
sufficient. For example, for a SNP with log(OR) of log(1.2), the na¨ıve sam-
ple size estimate centers around 222 with a maximum predicted size of 247,
while the true expected required sample size is 1170. Although both Ghosh
and B.BMA overestimate the necessary sample size for replication due to
the overcorrection of effect size, we believe that a conservative sample size
estimate is practically useful because it guards against sampling variation.
We also examined different effect levels when the type I error level is
equal to 0.05 or 0.001, and we drew similar conclusions based on the results
reported in Supplement. The additional simulation studies also include a null
case where the apparent discovery is a false positive. In that case, B.BMA
outperforms Ghosh, but B.L performs the best, as expected.
6. Application study. We applied the proposed Bayesian estimation meth-
ods to four data sets of which one is a candidate gene study and the other
three are genome-wide association studies (GWAS) of either binary or quan-
titative outcomes. Specifically, the four studies are as follows:
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Fig. 4. Performance of the nine estimators under an additive genetic model with a type 1
error rate of α= 2.87×10−7(c= 5). The sample size is 1000 (500 cases and 500 controls),
the minor allele frequency of the causal SNP is 0.25. The effect of the SNP on the log
OR scale ranging from µ = β = log(1.2), log(1.3), log(1.4) to log(1.8) corresponding to
power <1%, ≈5%, ≈20% and >95% to detect the association. Each circle represents an
estimate, the horizontal bar is the average estimate over 200 simulated data sets, and the
long horizontal line represents the true value of µ. The Bias, sample Standard Deviation
(SD) and Root Mean Squared Error (RMSE) are also provided for each estimator.
(I) the candidate gene association study of Lymphoma by Wang et al.
(2006),
(II) the GWAS of type 1 diabetes (T1D) by WTCCC (2007),
(III) the GWAS of psoriasis by Nair, Duffin and Helms (2009),
(IV) the GWAS of complications of T1D by Paterson et al. (2010).
The Lymphoma and WTCCC T1D data sets were chosen because they were
previously analyzed by Ghosh, Zou and Wright (2008) via the likelihood-
based approach, and the other two studies were chosen because the genetic
effect estimates from independent replication samples were reported by the
study authors. In addition, the T1D complication data set allows us to
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Fig. 5. Performance of sample size estimation for replication studies under an additive
genetic model. The initial discovery samples are the same as those in Figure 4. The repli-
cation sample size is calculated assuming a type 1 error rate of 0.05 and power of 80%,
and it is calculated based on the estimate of the log OR by N, the na¨ıve estimation method,
Ghosh, the likelihood method, or B.BMA, the Bayesian method applied to the simulated
significant discovery samples. Each circle represents an estimate, the horizontal bar is the
average estimate over 200 simulated data sets, and the long horizontal line represents the
true expected required sample size.
demonstrate that the proposed methods can be easily and robustly applied
to association studies of quantitative outcomes.
In each case, the results are summarized in a table containing the original
reported genetic effect (i.e., the na¨ıve estimate, N), the five different Bayesian
estimators, B.L, B.H, B.BMA, B.Unif and B.M, and three likelihood meth-
ods, MLE, NMLE and Ghosh, as described in Section 5. The estimates pro-
duced by each method are compared with the estimates obtained from the
independent replication samples reported in the literature. We note that the
anticipated power for each study differs due to the apparent differences in
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study design [e.g., higher power for the candidate gene study of Wang et al.
(2006) compared to the GWAS], the sample size [e.g., higher power for the
GWAS of T1D by WTCCC (2007) with n≈ 5000 compared to the GWAS
of T1D complication by Paterson et al. (2010) with n= 667], and the prior
knowledge of a SNP (e.g., higher power for rs12191877 from chromosome
6 in the well-known MHC region that is strongly associated with Psoriasis
compared to other novel SNPs). However, we report estimates from all five
Bayesian estimators for a more complete comparison. The estimate from the
replication samples serves as the benchmark, but the value itself should not
be viewed as the true parameter value because of the sampling variation
and the potential subpopulation and ascertainment differences between the
original discovery and the follow-up replication studies.
We also report the corresponding confidence interval (CI) or the highest
posterior density region/interval (HpdI), but it should be noted that the
statistical interpretations of CI and HpdI are different and, therefore, these
regions are not directly comparable. Although the HpdI with posterior mass
1− η may be estimated using samples from the posterior under model M1
for B.L or M2 for B.H, there is no direct way to construct a HPD region for
B.BMA, the model averaging estimator for the two models. However, a credi-
ble interval (CrdI) can be constructed using the normal approximation based
on the model averaging estimator and its variance estimate [see equation
(7) in Viallefont, Raftery and Richardson (2001)]. For the likelihood-based
methods, we construct the CI following the method proposed by Ghosh, Zou
and Wright (2008) that was shown to outperform the standard CI proce-
dure. Specifically, the Ghosh 1− η CI is the interval between the η/2 and
1− η/2 quantiles of the conditional density p(Tn|Tn > c). Ghosh, Zou and
Wright (2008) noted that, although they proposed three competing point
estimates, MLE, NMLE and Ghosh, their procedure provided only a single
CI.
6.1. Application I—A candidate-gene study of lymphoma. Wang et al.
(2006) performed a candidate gene study of Lymphoma using a total of
48 SNPs genotyped on 318 cases and 766 controls, and they reported two
significant SNPs using a p-value threshold of α= 0.002. The na¨ıve log OR
estimate is log(1.54) for rs1800629 and log(1.40) for rs909253, however, the
follow-up estimates obtained from a larger independent study are reduced
considerably to log(1.29) for rs1800629 and log(1.16) for rs909253 [Rothman
et al. (2006); Ghosh, Zou and Wright (2008)]. For each of the two SNPs, we
applied the likelihood estimation methods as well as the Bayesian meth-
ods, using the na¨ıve log OR estimates, µˆ = βˆ, and S = σˆ = ŜE (βˆ) × √n
inferred from the observed association p-value [p-value = 1−Φ(|βˆ/ŜE (βˆ)|)],
n= 318 + 766 = 1084 and c= 2.878 corresponding to α= 0.002 (Table 2).
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Table 2
Application I—the candidate gene study of Lymphoma by Wang et al. (2006)
SNPs of interest rs1800629 rs909253
Discovery samples
Association p-value 5.7× 10−4 7.4× 10−4
Reported effect 0.432 0.337
Likelihood estimates
MLE (CI) 0.116 (0.000, 0.645) 0.010 (0.000, 0.498)
NMLE (CI) 0.247 (0.000, 0.645) 0.184 (0.000, 0.498)
Ghosh (CI) 0.182 (0.000, 0.645) 0.097 (0.000, 0.498)
Bayesian estimates
B.L (HpdI) 0.005 (0.000, 0.013) 0.004 (0.000, 0.005)
B.H (HpdI) 0.196 (0.000, 0.508) 0.142 (0.000, 0.382)
B.BMA (CrdI) 0.150 (0.000, 0.428) 0.115 (0.000, 0.324)
B.Unif (HpdI) 0.068 (0.000, 0.377) 0.045 (0.000, 0.277)
B.M (HpdI) 0.074 (0.000, 0.397) 0.049 (0.000, 0.281)
Follow-up samples
Follow-up estimate 0.255 0.148
Notes: The Reported Effect is na¨ıve log OR estimate obtained from the original discovery
samples (318 cases and 766 controls) of Wang et al. (2006), in which the association
tests of these two SNPs were significant at the α= 0.002 level. The follow-up estimate was
obtained from a larger pooled analysis by Rothman et al. (2006). The other eight estimates
were based on either the likelihood approach, MLE, NMLE and Ghosh, or the proposed
Bayesian approach, B.L, B.H, B.BMA, B.Unif and B.M as summarized in Section 5. CI
is the 95% confidence interval for the likelihood estimates, HpdI is the highest posterior
density interval with posterior mass 95% and CrdI is the credible interval for the Bayesian
estimates.
Results in Table 2 are consistent with simulation results of power 50% in
Figure 2. Because of the anticipated high power of a candidate gene study,
both B.BMA and Ghosh overcorrect slightly with similar performance. We
observe that the CrdI of B.BMA is smaller than the CI of Ghosh, although
we noted before that the interpretation of the two intervals is different.
Results suggest that B.H performs best among all the Bayesian methods,
which is not surprising for a study with putative high power.
6.2. Application II—A GWAS of Type 1 Diabetes. The Type 1 Diabetes
(T1D) GWAS from the WTCCC included approximatively 2000 cases and
3000 controls and the samples were genotyped on the Affymetrix 500K chip3
[WTCCC (2007)]. After a set of quality control criterions (e.g., the minor
allele frequency of a SNP > 5%, the genotyping missing rate < 5% and the
p-value of the Hardy–Weinberg Equilibrium test > 5.7× 10−7), the authors
reported six significant loci at the 5 × 10−7 level. We focused on the four
SNPs analyzed by Ghosh, Zou and Wright (2008) because the replication
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results are available from the study of Todd et al. (2007). For each SNP
of interest, we applied the proposed estimation methods using the reported
log OR estimates obtained from the WTCCC discovery samples, βˆ = µˆ, and
S = σˆ = ŜE (βˆ) × √n inferred from the observed association p-value, and
c= 4.892 corresponding to α= 5× 10−7 (Table 3). In this application, the
actual number of cases is 1963 − 37 = 1926 and the number of controls is
(1480 − 24) + (1458 − 42) = 2872, where the 37, 24 and 42 samples were
deleted due to quality control issues, based on the information provided in
the supplementary Tables 1 and 4 of WTCCC (2007). Thus, n = 1926 +
2872 = 4798 in this application.
Results in Table 3 show that if the original association result is extreme in
that the p-value is considerably smaller than the threshold considered (i.e.,
rs17696736), then the prior influences the result only minimally. Similarly,
the likelihood-based estimates are only slightly reduced from the published
estimated log ORs. However, the follow-up estimate is considerably lower
than the bias reduced estimates. As noted by Ghosh, Zou and Wright (2008),
this suggests possible heterogeneity between the discovery and replication
samples. A subtle but important explanation for the results in the last three
columns of Table 3 where the replicated values are larger in absolute value
than the estimates produced by each method is that the follow-up estimates
here are also subject to the winner’s curse, albeit less severe, because only
estimates of successfully replicated SNPs were reported.
6.3. Application III—A GWAS of Psoriasis. Nair, Duffin and Helms
(2009) conducted a two-stage association of Psoriasis, a chronic skin dis-
ease characterized by circumscribed red patches covered with white scales.
The first stage is a GWAS with 438,670 SNPs genotyped on 1359 cases and
1400 controls, and the second stage is a replication study following up on
21 promising SNPs using a set of independent 5048 cases and 5051 controls.
“Owing to the winner’s curse, odds ratios estimated in the discovery sample
were larger than those estimated in the follow-up samples” [Table 2 of Nair,
Duffin and Helms (2009)]. The SNP selection criterion was mainly based
on the ranking of the GWAS p-value, roughly corresponding to a p-value
threshold of α= 10−4. For each SNP of interest, we applied the estimation
methods using the reported log OR estimates obtained from the discovery
samples, βˆ = µˆ, and S = σˆ = ŜE (βˆ) × √n inferred from the observed as-
sociation p-value, n = 1359 + 1400 = 2759 and c = 3.719 corresponding to
α= 10−4 (Table 4).
When the results are as extreme as rs12191877 with p= 4× 10−53 or as
rs2082412 with p= 5× 10−10, indicating high power at the chosen threshold
level, all the bias correction estimators results in little change from the
published estimate, including B.L despite its inherent prior skepticism of
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Table 3
Application II—the GWAS of T1D by WTCCC (2007)
SNPs of interest rs17696736 rs2292239 rs12708716 rs2542151
Discovery samples
Association p-value 7.27× 10−14 1.49× 10−9 1.28× 10−8 8.4× 10−8
Reported effect (CI) 0.315 (0.239, 0.399) 0.262 (0.182, 0.351) −0.261 (−0.357, −0.174) 0.285 (0.182, 0.399)
Likelihood estimates
MLE (CI) 0.314 (0.224, 0.397) 0.241 (0.095, 0.346) −0.212 (−0.348, 0.000) 0.140 (0.000, 0.375)
NMLE (CI) 0.310 (0.224, 0.397) 0.217 (0.095, 0.346) −0.182 (−0.348, 0.000) 0.154 (0.000, 0.375)
Ghosh (CI) 0.312 (0.224, 0.397) 0.229 (0.095, 0.346) −0.197 (−0.348, 0.000) 0.147 (0.000, 0.375)
Bayesian estimates
B.L (HpdI) 0.311 (0.221, 0.399) 0.019 (0.000, 0.210) −0.006 (−0.008, 0.000) 0.004 (0.000, 0.010)
B.H (HpdI) 0.309 (0.221, 0.403) 0.212 (0.063, 0.345) −0.170 (−0.306, 0.000) 0.126 (0.000, 0.294)
B.BMA (CrdI) 0.309 (0.234, 0.385) 0.207 (0.079, 0.336) −0.161 (−0.318, −0.004) 0.117 (0.000, 0.280)
B.Unif (HpdI) 0.311 (0.220, 0.398) 0.172 (0.000, 0.312) −0.087 (−0.283, 0.000) 0.045 (0.000, 0.240)
B.M (HpdI) 0.309 (0.211, 0.391) 0.173 (0.000, 0.310) −0.092 (−0.286, 0.000) 0.046 (0.000, 0.249)
Follow-up samples
Follow-up estimate (CI) 0.148 (0.086, 0.207) 0.247 (0.182, 0.308) −0.186 (−0.248, −0.116) 0.254 (0.174, 0.337)
Notes: The reported effect is na¨ıve log OR estimate obtained from the original discovery samples (1926 cases and 2872 controls) of
WTCCC (2007), in which the association tests of these SNPs were significant at the α= 5× 10−7 level. The Follow-up Estimate was
obtained from the replication study by Todd et al. (2007). The other eight estimates were based on either the likelihood approach, MLE,
NMLE and Ghosh, or the proposed Bayesian approach, B.L, B.H, B.BMA, B.Unif and B.M as summarized in Section 5. CI is the 95%
confidence interval for the likelihood estimates, HpdI is the highest posterior density interval with posterior mass 95% and CrdI is the
credible interval for the Bayesian estimates.
B
A
Y
E
S
IA
N
M
E
T
H
O
D
S
F
O
R
W
IN
N
E
R
’S
C
U
R
S
E
2
5
Table 4
Application III—the GWAS of Psoriasis by Nair, Duffin and Helms (2009)
SNPs of interest rs12191877 rs2082412 rs17728338 rs20541 rs610604
Discovery samples
p-value 4× 10−53 5× 10−10 2× 10−7 6× 10−6 1× 10−5
Reported effect 1.026 0.445 0.542 0.315 0.247
Likelihood estimate
MLE (CI) 1.026 (0.895, 1.157) 0.443 (0.287, 0.585) 0.514 (0.214, 0.746) 0.234 (0.000, 0.445) 0.162 (0.000, 0.349)
NMLE (CI) 1.026 (0.895, 1.157) 0.435 (0.287, 0.585) 0.476 (0.214, 0.746) 0.210 (0.000, 0.445) 0.154 (0.000, 0.349)
Ghosh (CI) 1.026 (0.895, 1.157) 0.439 (0.287, 0.585) 0.495 (0.214, 0.746) 0.222 (0.000, 0.445) 0.158 (0.000, 0.349)
Bayesian estimate
B.L (hpdI) 1.026 (0.887, 1.153) 0.400 (0.000, 0.556) 0.049 (0.000, 0.494) 0.007 (0.000, 0.010) 0.005 (0.000, 0.009)
B.H (hpdI) 1.024 (0.891, 1.150) 0.436 (0.276, 0.587) 0.468 (0.170, 0.754) 0.197 (0.000, 0.377) 0.136 (0.000, 0.288)
B.BMA (CrdI) 1.024 (0.915, 1.132) 0.436 (0.304, 0.568) 0.444 (0.151, 0.738) 0.172 (0.000, 0.379) 0.122 (0.000, 0.279)
B.Unif (hpdI) 1.026 (0.898, 1.163) 0.437 (0.283, 0.592) 0.405 (0.000, 0.681) 0.094 (0.000, 0.339) 0.062 (0.000, 0.252)
B.M (hpdI) 1.026 (0.887, 1.146) 0.436 (0.268, 0.580) 0.402 (0.000, 0.687) 0.096 (0.000, 0.341) 0.063 (0.000, 0.253)
Follow-up samples
Follow-up estimate 0.971 0.365 0.464 0.239 0.174
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Table 4
(Continued)
SNPs of interest rs2066808 rs2201841 rs1076160 rs12983316
Discovery samples
Association p-value 2× 10−5 3× 10−7 2× 10−5 2× 10−5
Reported effect 0.519 0.300 0.231 0.308
Likelihood estimates
MLE (CI) 0.231 (0.000, 0.728) 0.281 (0.107, 0.414) 0.103 (0.000, 0.324) 0.137 (0.000, 0.432)
NMLE (CI) 0.293 (0.000, 0.728) 0.258 (0.107, 0.414) 0.129 (0.000, 0.324) 0.173 (0.000, 0.432)
Gho0sh (CI) 0.262 (0.000, 0.728) 0.270 (0.107, 0.414) 0.116 (0.000, 0.324) 0.155 (0.000, 0.432)
Bayesian estimates
B.L (HpdI) 0.008 (0.000, 0.011) 0.021 (0.000, 0.228) 0.003 (0.000, 0.005) 0.004 (0.000, 0.010)
B.H (HpdI) 0.247 (0.000, 0.571) 0.253 (0.076, 0.422) 0.110 (0.000, 0.257) 0.147 (0.000, 0.340)
B.BMA (CrdI) 0.221 (0.000, 0.54) 0.240 (0.074, 0.407) 0.097 (0.000, 0.239) 0.127 (0.000, 0.316)
B.Unif (HpdI) 0.097 (0.000, 0.472) 0.207 (0.000, 0.381) 0.042 (0.000, 0.209) 0.056 (0.000, 0.275)
B.M (HpdI) 0.099 (0.000, 0.482) 0.210 (0.000, 0.376) 0.044 (0.000, 0.213) 0.057 (0.000, 0.273)
Follow-up samples
Follow-up estimate 0.293 0.122 0.086 0.086
Notes: The reported effect is na¨ıve log OR estimate obtained from the original discovery samples (1359 cases and 1400 controls) of
Nair, Duffin and Helms (2009), in which these SNPs were among the top 2000 SNPs based on the p-values of the association tests,
corresponding to α= 10−4 level. The Follow-up estimate was obtained from the replication study by Nair, Duffin and Helms (2009). The
other eight estimates were based on either the likelihood approach, MLE, NMLE and Ghosh, or the proposed Bayesian approach, B.L,
B.H, B.BMA, B.Unif and B.M as summarized in Section 5. CI is the 95% confidence interval for the likelihood estimates, HpdI is the
highest posterior density interval with posterior mass 95% and CrdI is the credible interval for the Bayesian estimates.
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a finding. For the other less significant SNPs in the table, both B.BMA
and Ghosh achieve substantial bias reduction. In general, B.BMA has a
noticeably smaller variance for lower power cases, which in turn can produce
more reliable sample size estimates for replication studies.
6.4. Application IV—A GWAS of quantitative measures of T1D compli-
cations. In the fourth setting of the GWA study of longitudinal repeated
quantitative measures of phenotype HbA1c in the Diabetes Control and
Complications Trial (DCCT) samples, a significant locus (at α= 5× 10−8)
was identified in the conventional treatment group with 667 samples near
SORCS1 (rs1358030 with p-value = 4.66 × 10−9). The association statis-
tic was obtained via regression analysis of the average log (HbA1c) value
vs. SNP with an additive genotype coding. The GWAS was performed on
841,342 SNPs, genotyped by the Illumina 1M BeadArray assay, that passed
a set of quality control criteria [details in Paterson et al. (2010)].
The na¨ıve estimate of the regression coefficient for rs1358030 is 0.045.
However, the estimate obtained from the intensive treatment group with
637 samples is 0.005 (Table 5). Note that for the intensive treatment group,
only the measures at the eligibility time-point (i.e., before the starting of
the two different treatments) were used for the regression analysis so that
the two groups are comparable and the intensive treatment group could be
used as a replication data set.
Unlike the case control studies with binary response (diseased or not)
considered previously, of interest here is a quantitative outcome, HbA1c, that
measures the amount of glycated hemoglobin in blood. Therefore, the µ no
longer represents the log OR but the corresponding coefficient in the linear
regression model. Although we could consider choosing a more suitable prior,
we adopted the same Uniform(0,2) density for f(µ) as for the case-control
data to test the robustness of the Bayesian methods. (Results from other
prior choices are discussed in Section 7.) To apply the Bayesian methods,
we let µˆ = 0.045, n = 667, c = 5.328 (corresponding to the threshold used,
the significance level is α= 5× 10−8), and the observed association p-value
4.66 × 10−9 (corresponding to a test statistic of 5.743) allows us to infer
the standard error S = µ ∗√n/5.743 = 0.202 (Table 5). As expected for the
low power case, both B.BMA and Ghosh reduce the estimation bias but
not sufficiently enough, and B.L performs better. However, in this case the
estimates from B.Unif or B.M are closest to the one obtained from the
follow-up study.
7. Conclusions and future work. We propose hierarchical Bayes meth-
ods to reduce selection bias in genetic association studies. The basis of the
approach is a spike-and-slab prior which essentially allows for the possibil-
ity that the signal detected may be a false positive. The prior permits the
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researchers to quantify their belief in the strength of the signal. Depending
on the prior, inference based on the posterior distribution may be differ-
ent from model to model and, therefore, the researcher faces a (sometimes
difficult) choice. To alleviate this dilemma, we consider a Bayesian model
averaging strategy, B.BMA, in which we use the data to weigh in on the
more appropriate model.
Simulation and application studies demonstrated that the B.BMA esti-
mator performs well across different settings, and we recommend B.BMA
when there is little information on the putative power of the initial discovery
study. However, we also emphasize that model averaging is not necessarily
the best approach for a given study. Factors such as study design and sample
size should be taken into account in the decision of using a more conservative
model like B.L or an anti-conservative one like B.H. In general, B.H is suit-
Table 5
Application IV—the GWAS of HbA1c in Type 1 Diabetes
patients, by Paterson et al. (2010)
SNP of interest rs1358030
Discovery samples
Association p-value 4.66× 10−9
Reported effect 0.045
Likelihood estimates
MLE (CI) 0.029 (0.000, 0.056)
NMLE (CI) 0.024 (0.000, 0.056)
Ghosh (CI) 0.027 (0.000, 0.056)
Bayesian estimates
B.L (HpdI) 0.001 (0.000, 0.002)
B.H (HpdI) 0.021 (0.000, 0.048)
B.BMA (CrdI) 0.020 (0.000, 0.047)
B.Unif (HpdI) 0.007 (0.000, 0.040)
B.M (HpdI) 0.008 (0.000, 0.040)
Follow-up samples
Follow-up estimate 0.005
Notes: The reported effect is the na¨ıve estimate of the regres-
sion coefficient obtained from the 667 discovery samples, in
which the association test of the SNP was significant at the
α= 5× 10−8 level. The Follow-up estimate was obtained from
637 independent samples. The other eight estimates were based
on either the likelihood approach, MLE, NMLE and Ghosh, or
the proposed Bayesian approach, B.L, B.H, B.BMA, B.Unif
and B.M as summarized in Section 5. CI is the 95% confidence
interval for the likelihood estimates, HpdI is the highest poste-
rior density interval with posterior mass 95% and CrdI is the
credible interval for the Bayesian estimates.
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able for candidate gene studies with putative high power as demonstrated
in application I, and B.L is preferred for GWAS with putative low power
as shown in application IV. Knowledge about the SNP of interest is also a
factor. For example, little bias is expected for a SNP in a well-known asso-
ciated region or with p-value significantly smaller than the chosen threshold
as demonstrated by the first SNP (rs12191877) in Table 4 of application
III, while substantial bias is expected for a SNP with p-value just below the
threshold as shown by the last SNP (rs12983316) in the table.
We have carried out additional simulation studies to investigate the ro-
bustness of the Bayesian estimators. Results provided in Supplement show
that the proposed methods are robust to the choice of prior for ξ, the hy-
perparameter that reflects our prior belief in false positive, to the number
of iterations discarded from the MCMC sample, and to the value of A, the
prior upper bound of log odds ratio. In addition, we developed our meth-
ods using a conceptual normal model but demonstrated via simulations and
applications that this normal model is well connected with widely used real
genetic models and is robust to the choice of priors. For example, in applica-
tion IV when the phenotype is not a case-control status but a quantitative
outcome, we kept the same A= 2 knowing that the the upper bound for µ,
the genetic effect size, in this case can be reasonably assumed to be 0.2. To
be more precise, note that µ is a regression coefficient in this setup and is
related to the percentage of phenotype variation explained by the SNP via
the expression
r2 = µ2
S2X
S2Y
,
where S2X ≈ 0.467 is the sample variance of the SNP and S2Y ≈ 0.018 is the
sample variance of the phenotype. Since r2 ≤ 100%, thus, µ ≤ 0.2. When
A = 0.2 was assumed, the estimates were largely unchanged compared to
results in Table 5: 0.00062 (0, 0.001) for B.L, 0.021 (0.000, 0.0474) for B.H,
0.0197 (0, 0.0456) for B.BMA, 0.0077 (0.000, 0.03996) for B.Unif and 0.0084
(0.000, 0.0407) for B.M. If a true effect is greater than 2, our Bayesian
estimations will be bounded by 2. In practice, if the true OR is greater
than exp(2)≈ 7.4, then the putative power of the original association study
is very high (unless the sample size is extremely small), resulting in little
estimation bias of the na¨ıve estimate. Second, if a Bayesian estimate was
close to the upper bound, then one can choose a bigger value such as 6. This
modification does not affect the estimation for the cases when the effects
are less than 2 (confirmed by our additional simulation studies) but provide
better effect estimates when the true effects are indeed greater than 2. The
proposed Bayesian methods, however, are not robust to the misspecification
of the threshold used. This type of sensitivity was also observed for other
existing methods including the likelihood and resampling based methods.
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The NMLE estimator proposed by Ghosh, Zou and Wright (2008) is the
mean of the normalized conditional likelihood, and it can be interpreted as
the posterior mean with an improper flat prior on µ which should produce
similar results to B.Unif. However, unlike NMLE, our model allows a point
mass on effect being equal to 0 via the spike-and-slab prior, leading to a
better performance than NMLE. As an average of the conditional MLE and
the NMLE estimators, the Ghosh estimator strikes a balance between the
two and performs better than both across different settings. Although Ghosh
and B.BMA can have similar performance in some settings, the advantage of
the proposed Bayesian estimator is clear and meaningful. For example, the
standard error in sample size estimation based on B.BMA is almost twice
as small as that based on Ghosh when the power of the original association
study is low as shown in Figure 5.
Both the likelihood and Bayesian methods correct for threshold effect (i.e.,
the SNP of interest must pass a significance threshold) by incorporating the
threshold value in the models. In practice, another source of bias is the rank-
ing effect. More precisely, suppose that a large number of SNPs are consid-
ered but only the effects for top ranked SNPs are estimated. Again, the effect
estimate is biased but a likelihood-based correction is cumbersome since all
SNPs (with complex correlation structure among them due to linkage dise-
quilibrium) must be considered jointly. The proposed Bayesian method only
indirectly models the ranking effect by allowing the SNP of interest to be
false positive. So far, the method of choice for this problem remains the
bootstrap-based correction method of Sun and Bull (2005). However, the
bootstrap method requires the original individual specific data which can
be limiting. In contrast, the Bayesian and the likelihood approaches only
need the summary statistics such as the reported na¨ıve estimate and the as-
sociation p-value, and the auxiliary information such as the sample size and
the threshold used. In a two-stage setting when both the original discovery
scan and a replication study are available, the combined approach proposed
by Bowden and Dudbridge (2009) could provide better estimation results.
Although the method proposed here falls within the Bayesian paradigm,
it has a clear frequentist component since the sampling distribution is condi-
tional on the significance of the hypothesis test. While a complete Bayesian
analysis in which simultaneous testing and estimation is possible for the
problems considered here, it must be noted that the current practice among
genetic investigators is to perform a large number of individual association
tests prior to moving on to the estimation stage, in part due to the com-
putational challenges associated with analyzing 500,000 or more SNPs. It is
for this reason and to address the bias incurred by the resulting inference
that we chose to use the current model. A full joint Bayesian analysis is the
subject of ongoing research.
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SUPPLEMENTARY MATERIAL
Supplement: Additional Derivations and Simulation Plots
(DOI: 10.1214/10-AOAS373SUPP; .pdf). The appendix contains derivations
related to posterior computation and additional simulation results related
to the robustness of the Bayesian model considered to the choice of prior.
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